Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
What does it do?
Medtronic makes medical devices — the physical hardware that doctors use to treat serious health conditions inside your body. Think pacemakers that keep hearts beating in rhythm, insulin pumps for diabetics, or robotic surgery tools that help surgeons operate more precisely. If you've ever had a family member fitted with a heart device or spinal implant, there's a decent chance it was made by Medtronic. They sell to hospitals, clinics, and doctors in over 150 countries.
Medtronic is one of the largest medical device companies on the planet with a $103 billion market value, meaning it's a bellwether — when it reports results, the whole medical device sector pays attention. Aging populations in the US, Europe, and Asia are driving demand for exactly the kinds of heart, spine, and diabetes products Medtronic specializes in. After a rough few years of post-pandemic supply issues and a slow diabetes device turnaround, investors are watching closely to see if the recovery is real.
How does it make money?
Medtronic makes money by selling physical medical devices and the software services that go with them across four main divisions: Cardiovascular (heart devices like pacemakers), Medical Surgical (tools used in operating rooms), Neuroscience (spine and brain therapies), and Diabetes (insulin pumps and glucose monitors). Revenue grew from $33.5 billion to $36.3 billion in the latest year — a solid 8% jump. They earn recurring revenue too, since many devices need regular consumables, software subscriptions, or replacement parts, which makes their income more predictable than a one-time sale business.
Why do investors care?
The core growth story is that the world is getting older and sicker, and Medtronic has decades of patents, clinical data, and hospital relationships that are extremely hard for a newcomer to replicate. Investors are also excited about specific product cycles — their Micra leadless pacemaker, Simplera Sync insulin sensor, and Hugo robotic surgery system are all newer bets that could meaningfully grow market share. For the thesis to work, the diabetes turnaround needs to continue, the robotics platform needs to gain hospital adoption, and cost-cutting under the current CEO needs to translate into fatter profit margins.
Deep Dive
MemberA full investor briefing on Medtronic plc — history, leadership, risks, and outlook.